Leukocytoclastic vasculitis secondary to clozapine

Leukocytoclastic vasculitis (LCV) may be secondary to drugs, underlying infection, collagen vascular disorders, or malignancy. Drug-induced vasculitis contributes to 10% of vasculitic skin lesions cases usually developing within 7–21 days of treatment initiation. The present case highlights a report of LCV in a 59-year-old male with a history of paranoid schizophrenia on clozapine therapy. The report upsurges the need to promote awareness and expedite diagnosis and treatment of drug-induced LCVs.

[1]  T. Hodgson,et al.  Leukocytoclastic Vasculitis Secondary to Pyridostigmine (Mestinon): Report of a Possible First Case. , 2017, The Permanente journal.

[2]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.

[3]  T. Lotti,et al.  Cutaneous necrotizing vasculitis. Relation to systemic disease. , 1999, Advances in experimental medicine and biology.

[4]  Aditya M. Sharma,et al.  Diagnostic approach in patients with suspected vasculitis. , 2014, Techniques in vascular and interventional radiology.

[5]  R. Falk,et al.  Cutaneous and Systemic Manifestations of Drug-Induced Vasculitis , 2002, The Annals of pharmacotherapy.

[6]  P. Schneider,et al.  Preventability and severity assessment in reporting adverse drug reactions. , 1992, American journal of hospital pharmacy.

[7]  J. Jorizzo,et al.  Small‐vessel vasculitis , 2012, Dermatologic therapy.

[8]  R. Kelly,et al.  Retrospective analysis of adult patients with cutaneous leukocytoclastic vasculitis , 2006, The Australasian journal of dermatology.

[9]  T. Lotti,et al.  Cutaneous small-vessel vasculitis. , 1998, Journal of the American Academy of Dermatology.

[10]  E. Matteson,et al.  Small vessel vasculitis History, classification, etiology, histopathology, clinic, diagnosis and treatment , 2007 .

[11]  L. Calabrese,et al.  Diagnosis and treatment of cutaneous leukocytoclastic vasculitis , 2013 .